Outlined as the total market value of all unsettled shares of the company, the current market cap for the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Biotechnology is valued at 36911.66. The dominant statistics will authorize the investment community to govern the size of Regeneron Pharmaceuticals, Inc. compared to the sales or total assets figures. Consequently, investors will be able to grasp the rudimentary determinant of asset distribution and all kinds of risk-return parameters for stocks together with the stock mutual funds. Nevertheless, it is a common misunderstanding that a greater share price directs towards a larger company where stock price might also twist the definite worth of the organization.
The current assessment forRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Biotechnology on its PE ratio displays a value of 53.91 with a Forward PE of 21.89. Regeneron Pharmaceuticals, Inc. Biotechnology has a PEG of 2.85 alongside a PS value of 8.32 and a PB value of 9.4.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Biotechnology shows a Dividend Yield of with a Payout Ratio of 0.00%. Regeneron Pharmaceuticals, Inc. Biotechnology holds an EPS of 6.3 that demonstrates an EPS growth this year at 85.10%. The growth for the next year comes down to 43.12%, and its growth for the last five years shows at 44.90%. Eventually, Regeneron Pharmaceuticals, Inc. Biotechnology exhibits an EPS value of 18.89% for the next five years. Sales growth in the quarter for Regeneron Pharmaceuticals, Inc. Biotechnology NASDAQ shows a value of 38.10% with Outstanding shares of 108.73.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Biotechnology has a Current Ratio of 3.4 with a Quick Ratio value of 3.1. The firm shows a 20-Day Simple Moving Average of -11.87% with a 200-Day Simple Moving Average of -25.42%. Its Day High was -25.42% and Day Low showed -0.45%. The 52-Week High shows -43.97% with a 52-Week Low of -0.45%.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Biotechnology has a current market price of 339.48 and the change is -4.94%. Its Target Price was fixed at 473.48 at an IPO Date of 04/02/1991. At present, the Gross Margin for Regeneron Pharmaceuticals, Inc. REGN Biotechnology is moving around at 90.50% alongside a Profit Margin of 16.40%. Performance week shows a value of -4.16%, and the Performance for the Month is valued at -13.94%. Volatility for the week appears to be 3.55% in conjunction with the Volatility for the month at 2.81%.
Disclaimer: Outlined statistics and information communicated in the above editorial are merely a work of the authors. They do not ponder or echo the certified policy or position of any business stakeholders, financial specialists, or economic analysts. Specimens laid down on the editorial above are only cases with information collected from various sources. The authority will not be liable for anyone who makes stock portfolio or financial decisions as per the editorial, which is based only on limited and open source.